Which has stronger valuation & earnings, VCYT or TWST?

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 8.87 $66.35M $1.09 52.73 Twist Bioscience $376.57M 14.94 -$77.67M -$1.33 N/A

Does the media refer more to VCYT or TWST?

In the previous week, Veracyte had 1 more articles in the media than Twist Bioscience. MarketBeat recorded 9 mentions for Veracyte and 8 mentions for Twist Bioscience. Veracyte's average media sentiment score of 1.26 beat Twist Bioscience's score of 0.52 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BTSG or VCYT?

In the previous week, BrightSpring Health Services had 4 more articles in the media than Veracyte. MarketBeat recorded 13 mentions for BrightSpring Health Services and 9 mentions for Veracyte. Veracyte's average media sentiment score of 1.26 beat BrightSpring Health Services' score of 0.19 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BrightSpring Health Services 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Veracyte 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to FMS or VCYT?

In the previous week, Veracyte had 5 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 9 mentions for Veracyte and 4 mentions for Fresenius Medical Care AG & Co. KGaA. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 1.30 beat Veracyte's score of 1.26 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fresenius Medical Care AG & Co. KGaA 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, HIMS or VCYT?

Hims & Hers Health has higher revenue and earnings than Veracyte. Hims & Hers Health is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hims & Hers Health $2.35B 3.39 $128.37M -$0.09 N/A Veracyte $517.15M 8.87 $66.35M $1.09 52.73

Does the media prefer HIMS or VCYT?

In the previous week, Hims & Hers Health had 3 more articles in the media than Veracyte. MarketBeat recorded 12 mentions for Hims & Hers Health and 9 mentions for Veracyte. Veracyte's average media sentiment score of 1.26 beat Hims & Hers Health's score of 0.63 indicating that Veracyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Veracyte 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, VCYT or PACS?

PACS Group has higher revenue and earnings than Veracyte. PACS Group is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 8.87 $66.35M $1.09 52.73 PACS Group $5.29B 1.30 $191.54M $1.56 27.75

Is VCYT or PACS more profitable?

Veracyte has a net margin of 16.25% compared to PACS Group's net margin of 4.49%. PACS Group's return on equity of 26.47% beat Veracyte's return on equity. Company Net Margins Return on Equity Return on Assets Veracyte 16.25% 9.07% 8.38% PACS Group 4.49% 26.47% 4.36%

Does the media prefer VCYT or PACS?

In the previous week, PACS Group had 7 more articles in the media than Veracyte. MarketBeat recorded 16 mentions for PACS Group and 9 mentions for Veracyte. Veracyte's average media sentiment score of 1.26 beat PACS Group's score of 0.07 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PACS Group 4 Very Positive mention(s) 7 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Veracyte (VCYT) Competitors

$57.48 +0.51 (+0.90%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$57.44 -0.04 (-0.08%)

As of 04:23 AM Eastern

Compare

VCYT vs. TWST, BTSG, FMS, HIMS, and PACS

Should you buy Veracyte stock or one of its competitors? MarketBeat compares Veracyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Veracyte include Twist Bioscience (TWST), BrightSpring Health Services (BTSG), Fresenius Medical Care AG & Co. KGaA (FMS), Hims & Hers Health (HIMS), and PACS Group (PACS). These companies are all part of the "medical" sector.

How does Veracyte compare to Twist Bioscience?

Veracyte (NASDAQ:VCYT) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	8.87	$66.35M	$1.09	52.73
Twist Bioscience	$376.57M	14.94	-$77.67M	-$1.33	N/A

In the previous week, Veracyte had 1 more articles in the media than Twist Bioscience. MarketBeat recorded 9 mentions for Veracyte and 8 mentions for Twist Bioscience. Veracyte's average media sentiment score of 1.26 beat Twist Bioscience's score of 0.52 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veracyte has a net margin of 16.25% compared to Twist Bioscience's net margin of -19.85%. Veracyte's return on equity of 9.07% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	16.25%	9.07%	8.38%
Twist Bioscience	-19.85%	-26.73%	-19.15%

Veracyte presently has a consensus price target of $51.86, indicating a potential downside of 9.78%. Twist Bioscience has a consensus price target of $84.30, indicating a potential downside of 6.70%. Given Twist Bioscience's higher probable upside, analysts clearly believe Twist Bioscience is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Twist Bioscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Veracyte has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.11, indicating that its stock price is 111% more volatile than the broader market.

Summary

Veracyte beats Twist Bioscience on 11 of the 15 factors compared between the two stocks.

How does Veracyte compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSG) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

BrightSpring Health Services presently has a consensus target price of $68.41, suggesting a potential downside of 1.76%. Veracyte has a consensus target price of $51.86, suggesting a potential downside of 9.78%. Given BrightSpring Health Services' stronger consensus rating and higher possible upside, research analysts plainly believe BrightSpring Health Services is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BrightSpring Health Services	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00
Veracyte	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

BrightSpring Health Services has higher revenue and earnings than Veracyte. BrightSpring Health Services is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BrightSpring Health Services	$12.91B	1.06	$190.67M	$1.41	49.39
Veracyte	$517.15M	8.87	$66.35M	$1.09	52.73

In the previous week, BrightSpring Health Services had 4 more articles in the media than Veracyte. MarketBeat recorded 13 mentions for BrightSpring Health Services and 9 mentions for Veracyte. Veracyte's average media sentiment score of 1.26 beat BrightSpring Health Services' score of 0.19 indicating that Veracyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BrightSpring Health Services	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Veracyte	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veracyte has a net margin of 16.25% compared to BrightSpring Health Services' net margin of 2.27%. BrightSpring Health Services' return on equity of 14.63% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BrightSpring Health Services	2.27%	14.63%	4.41%
Veracyte	16.25%	9.07%	8.38%

BrightSpring Health Services has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market.

Summary

BrightSpring Health Services beats Veracyte on 8 of the 15 factors compared between the two stocks.

How does Veracyte compare to Fresenius Medical Care AG & Co. KGaA?

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Fresenius Medical Care AG & Co. KGaA presently has a consensus target price of $28.00, suggesting a potential upside of 14.50%. Veracyte has a consensus target price of $51.86, suggesting a potential downside of 9.78%. Given Fresenius Medical Care AG & Co. KGaA's higher possible upside, equities research analysts plainly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fresenius Medical Care AG & Co. KGaA	4 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.56
Veracyte	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Veracyte. Fresenius Medical Care AG & Co. KGaA is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA	$22.20B	0.59	$1.11B	$1.90	12.87
Veracyte	$517.15M	8.87	$66.35M	$1.09	52.73

Fresenius Medical Care AG & Co. KGaA has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Veracyte has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market.

In the previous week, Veracyte had 5 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 9 mentions for Veracyte and 4 mentions for Fresenius Medical Care AG & Co. KGaA. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 1.30 beat Veracyte's score of 1.26 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fresenius Medical Care AG & Co. KGaA	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

8.4% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. 1.6% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Veracyte has a net margin of 16.25% compared to Fresenius Medical Care AG & Co. KGaA's net margin of 4.88%. Veracyte's return on equity of 9.07% beat Fresenius Medical Care AG & Co. KGaA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fresenius Medical Care AG & Co. KGaA	4.88%	8.90%	4.05%
Veracyte	16.25%	9.07%	8.38%

Summary

Veracyte beats Fresenius Medical Care AG & Co. KGaA on 11 of the 17 factors compared between the two stocks.

How does Veracyte compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Veracyte (NASDAQ:VCYT) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

In the previous week, Hims & Hers Health had 3 more articles in the media than Veracyte. MarketBeat recorded 12 mentions for Hims & Hers Health and 9 mentions for Veracyte. Veracyte's average media sentiment score of 1.26 beat Hims & Hers Health's score of 0.63 indicating that Veracyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Veracyte	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

63.5% of Hims & Hers Health shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by company insiders. Comparatively, 1.6% of Veracyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Hims & Hers Health currently has a consensus price target of $30.70, suggesting a potential downside of 10.75%. Veracyte has a consensus price target of $51.86, suggesting a potential downside of 9.78%. Given Veracyte's stronger consensus rating and higher possible upside, analysts clearly believe Veracyte is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	2 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
Veracyte	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78

Veracyte has a net margin of 16.25% compared to Hims & Hers Health's net margin of -0.56%. Veracyte's return on equity of 9.07% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
Veracyte	16.25%	9.07%	8.38%

Hims & Hers Health has a beta of 2.35, meaning that its share price is 135% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.93, meaning that its share price is 93% more volatile than the broader market.

Hims & Hers Health has higher revenue and earnings than Veracyte. Hims & Hers Health is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	3.39	$128.37M	-$0.09	N/A
Veracyte	$517.15M	8.87	$66.35M	$1.09	52.73

Summary

Veracyte beats Hims & Hers Health on 10 of the 16 factors compared between the two stocks.

How does Veracyte compare to PACS Group?

Veracyte (NASDAQ:VCYT) and PACS Group (NYSE:PACS) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Veracyte has a net margin of 16.25% compared to PACS Group's net margin of 4.49%. PACS Group's return on equity of 26.47% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	16.25%	9.07%	8.38%
PACS Group	4.49%	26.47%	4.36%

Veracyte has a beta of 1.93, suggesting that its share price is 93% more volatile than the broader market. Comparatively, PACS Group has a beta of -0.08, suggesting that its share price is 108% less volatile than the broader market.

Veracyte presently has a consensus price target of $51.86, suggesting a potential downside of 9.78%. PACS Group has a consensus price target of $50.60, suggesting a potential upside of 16.88%. Given PACS Group's higher possible upside, analysts clearly believe PACS Group is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

PACS Group has higher revenue and earnings than Veracyte. PACS Group is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	8.87	$66.35M	$1.09	52.73
PACS Group	$5.29B	1.30	$191.54M	$1.56	27.75

In the previous week, PACS Group had 7 more articles in the media than Veracyte. MarketBeat recorded 16 mentions for PACS Group and 9 mentions for Veracyte. Veracyte's average media sentiment score of 1.26 beat PACS Group's score of 0.07 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PACS Group	4 Very Positive mention(s)	7 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Veracyte beats PACS Group on 8 of the 15 factors compared between the two stocks.

Get Veracyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCYT vs. The Competition

Export

Metric	Veracyte	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.55B	$7.63B	$7.05B	$12.61B
Dividend Yield	N/A	1.32%	2.68%	8.00%
P/E Ratio	52.73	50.28	27.13	24.26
Price / Sales	8.87	76.45	589.11	117.88
Price / Cash	38.25	26.85	29.22	49.36
Price / Book	3.47	7.32	10.77	6.29
Net Income	$66.35M	$162.30M	$3.58B	$330.66M
7 Day Performance	2.35%	-0.99%	-2.10%	-1.32%
1 Month Performance	21.45%	0.19%	3.29%	-0.64%
1 Year Performance	115.68%	4.08%	26.34%	19.08%

Veracyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCYT Veracyte	2.8719 of 5 stars	$57.48 +0.9%	$51.86 -9.8%	+112.3%	$4.55B	$517.15M	52.73	790	Positive News Analyst Upgrade
TWST Twist Bioscience	1.7469 of 5 stars	$99.93 +0.7%	$84.30 -15.6%	+137.6%	$6.18B	$376.57M	N/A	990	Insider Trade
BTSG BrightSpring Health Services	2.5482 of 5 stars	$70.56 +2.2%	$63.67 -9.8%	+242.9%	$13.62B	$12.91B	55.67	23,500	Analyst Forecast
FMS Fresenius Medical Care AG & Co. KGaA	4.3149 of 5 stars	$23.62 +0.4%	$28.00 +18.5%	-9.6%	$12.64B	$22.20B	12.43	1,488	Positive News Gap Up
HIMS Hims & Hers Health	3.2174 of 5 stars	$38.34 +4.2%	$30.63 -20.1%	-28.2%	$8.52B	$2.35B	N/A	2,442

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCYT) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veracyte (VCYT) Competitors

VCYT vs. TWST, BTSG, FMS, HIMS, and PACS

How does Veracyte compare to Twist Bioscience?

Summary

How does Veracyte compare to BrightSpring Health Services?

Summary

How does Veracyte compare to Fresenius Medical Care AG & Co. KGaA?

Summary

How does Veracyte compare to Hims & Hers Health?

Summary

How does Veracyte compare to PACS Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT vs. The Competition

Veracyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veracyte (VCYT) Competitors

VCYT vs. TWST, BTSG, FMS, HIMS, and PACS

How does Veracyte compare to Twist Bioscience?

Which has stronger valuation & earnings, VCYT or TWST?

Does the media refer more to VCYT or TWST?

Is VCYT or TWST more profitable?

Do analysts prefer VCYT or TWST?

Which has more risk & volatility, VCYT or TWST?

Summary

How does Veracyte compare to BrightSpring Health Services?

Do analysts prefer BTSG or VCYT?

Which has stronger earnings and valuation, BTSG or VCYT?

Does the media refer more to BTSG or VCYT?

Is BTSG or VCYT more profitable?

Which has more risk and volatility, BTSG or VCYT?

Summary

How does Veracyte compare to Fresenius Medical Care AG & Co. KGaA?

Do analysts rate FMS or VCYT?

Which has preferable earnings and valuation, FMS or VCYT?

Which has more risk and volatility, FMS or VCYT?

Does the media refer more to FMS or VCYT?

Do insiders & institutionals have more ownership in FMS or VCYT?

Is FMS or VCYT more profitable?

Summary

How does Veracyte compare to Hims & Hers Health?

Does the media prefer HIMS or VCYT?

Do insiders and institutionals have more ownership in HIMS or VCYT?

Do analysts rate HIMS or VCYT?

Is HIMS or VCYT more profitable?

Which has more risk & volatility, HIMS or VCYT?

Which has stronger valuation and earnings, HIMS or VCYT?

Summary

How does Veracyte compare to PACS Group?

Is VCYT or PACS more profitable?

Which has more volatility and risk, VCYT or PACS?

Do analysts prefer VCYT or PACS?

Which has stronger earnings & valuation, VCYT or PACS?

Does the media prefer VCYT or PACS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT vs. The Competition

Veracyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools